{{$DoctorName}} @if(isset(session()->get('doctor')['vCentralCode'])) {{session()->get('doctor')['vCentralCode']}} @endif
@if(isset(session()->get('doctor')['vCentralCode']))
Logout
@endif

{{$ActivityTypeName}}

{{$ActivityName}}

@csrf
@if(isset(session()->get('doctor')['vCentralCode']))
Back
@else
@endif
Lipodox Survey 1
    {{--1--}}
  1. In your clinical practice, approximately how many newly diagnosed ovarian cancer patients do you see every year? *
    2. Patients/Year
    {{--2--}}
  2. In your clinical practice, what is percentage-wise split of ovarian cancer patients in following stages? *
    3. Stage I
    Stage-II
    Stage III
    Stage IV
    {{--3--}}
  3. In your clinical practice, approximately what percentage of ovarian cancer patients relapse in following period? *
    4. < 6 months
    %
    6 - 12 months
    %
    12 - 18 months
    %
    18 - 24 months
    %
    >24 months
    %
    {{--4--}}
  4. What is average PFS that you achieve in newly diagnosed ovarian cancer patients treated with Paclitaxel + Platinum agent? *
    5. Months
    {{--5--}}
  5. In your clinical practice, what % of your ovarian cancer patients receive Bevacizumab in *
    6. 1st Line
    %
    2nd Line
    %
    {{--6--}}
  6. When patient relapse within 6 months of 1L chemotherapy, what is approximate percentage of patients treated with following options? *
    7. PLD
    %
    Nano-Paclitaxel
    %
    Gemcitabine
    %
    {{--7--}}
  7. In your clinical practice, on an average how many cycles of PLD do most platinum resistant recurrent ovarian cancer patients takes? *
    8. Cycles
    {{--8--}}
  8. When patient relapse within 0-6 months of completion of 1L chemotherapy, what is approximate percentage of patients treated with following options? *
    9. Single agent
    %
    Combination with Bevacizumab
    %
    {{--9--}}
  9. When patient relapse within 6-12 months of completion of 1L chemotherapy, what is approximate percentage of patients treated with following options? *
    10. PLD + platinum agent
    %
    Gemcitabine + Platinum agent
    %
    Paclitaxel + Platinum agent
    %
    {{--10--}}
  10. When patient relapse within 12-18 months of completion of 1L chemotherapy, what is approximate percentage of patients treated with following options? *
    11. PLD + platinum ± Bevacizumab
    %
    Gemcitabine + Platinum ± Bevacizumab
    %
    Paclitaxel + Platinum ± Bevacizumab
    %
    {{--11--}}
  11. When patient relapse within 18-24 months of completion of 1L chemotherapy, what is approximate percentage of patients treated with following options? *
    12. PLD + platinum ± Bevacizumab
    %
    Gemcitabine + Platinum ± Bevacizumab
    %
    Paclitaxel + Platinum ± Bevacizumab
    %
    {{--12--}}
  12. When patient relapse after 24 months of completion of 1L chemotherapy, what is approximate percentage of patients treated with following options? *
    13. PLD + platinum ± Bevacizumab
    %
    Gemcitabine + Platinum ± Bevacizumab
    %
    Paclitaxel + Platinum ± Bevacizumab
    %
    {{--13--}}
  13. In your clinical practice, what % of newly diagnosed ovarian cancer patients treated with Carboplatin+Paclitaxel in 1st line suffer from neurotoxicity? *
    14. All Grade
    %
    Grade 3-4
    %
    {{--14--}}
  14. When ovarian cancer relapse after 1st line chemotherapy treatment, approximately what % of patients continue to have residual neurotoxicity at 12 months: *
    15. %
    {{--15--}}
  15. When ovarian cancer relapse after 1st line chemotherapy treatment, approximately what % of patients continue to have residual neurotoxicity at 24 months: *
    16. %